At the news
? BULLISHIMPACT 6/10 PRESS-RELEASE filed May 4, 2026 at 07:00 ET
Krystal Biotech reported strong Q1 2026 results with VYJUVEK revenue up 32% YoY to $116.4M and diluted EPS of $1.83, up 52.5% YoY. Pipeline advancements include complete enrollment for KB803 and on-track readouts for KB801 and KB407 in 2026.
- Q1 2026 VYJUVEK net product revenue of $116.4M, +32% YoY
- Diluted EPS of $1.83 vs $1.20 in Q1 2025
- Gross margin of 95% for Q1 2026
- Registrational studies for KB803 (DEB corneal abrasions) and KB801 (neurotrophic keratitis) on track for data readouts in 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access